Multiple sclerosis in Peru: National prevalence study using capture-recapture analysis
- Gonzales Gamarra O(corresponding author),
- Alva Diaz C(corresponding author),
- Pacheco Barrios K,
- Aguirre Quispe W,
- Malaga M,
- Inca J
- Peruvian Committee for Treatment and Research in Multiple Sclerosis (PECTRIMS),
- ,
- Universidad San Ignacio de Loyola,
- SYNAPSIS Mental Health and Neurology,
- docencia y atención especializada en epilepsia,
- Universidad de San Martin de Porres
Publication Information
Output type
Original language
EnglishArticle number
103147Journal (Volume, Issue Number)
Multiple Sclerosis and Related Disorders (Volume 55)Publication milestones
- Published - 10/2021
Publication status
ISSN
2211-0348Publication IDs
- Scopus: 85111819368
- PubMed: 34332455
Abstract
Background: There is scarce epidemiological data on Multiple Sclerosis (MS) in Latin America. National epidemiological studies are needed to guide the health policy related to MS. Objective: To determine MS national prevalence in Peru and describe clinical and epidemiological characteristics of the disease. Methods: We conducted a cross-sectional prevalence study in Peru's four largest regions using two sources. We included adult patients diagnosed with MS by a neurologist using the McDonald criteria. We performed a capture-recapture analysis using the nearly unbiased estimator model, and calculated prevalence as the proportion of the adult Peruvian population in 2016. Additionally, we summarized patients epidemiological and clinical characteristics. Results: We identified 417 cases: 135 from the first source and 282 from the one. We found a point prevalence of 9.12 cases per 100 000 inhabitants (95% CI: 5.6 - 12.6). The age range was 35 to 45 years-old, and 51.9% were female. The most common type of MS was relapsing-remitting (79.3%) and the most frequent treatment was subcutaneous IFN-1b (40.7%). Conclusion: Peru has a medium MS prevalence compared to other Latin American countries.
Access to documents
Publication metrics
Metrics
Sustainable Development Goals
- SDG 3 Good Health and Well
